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Objectives. We evaluated coagulability as determined by
platelet-dependent thrombin generation in hypercholesterolemic
patients before and after treatment with pravastatin and in
hypertriglyceridemic patients to investigate the usefulness of
coagulability as an index of atherosclerosis and to determine the
importance of treating hyperlipidemia.
Background. An understanding of the interaction between
platelets and the plasma coagulation system is important for
clarifying the mechanism of the procoagulant process.
Methods. We assessed coagulability in 58 patients with hyper-
cholesterolemia (serum total cholesterol level >2220 mg/dl, age
56.5 6 1.5 years [mean 6 SEM]), 37 patients with hypertriglyc-
eridemia (serum triglyceride level >2200 mg/dl, age 59.5 6 1.7
years), 13 patients with hypercholesterolemia plus hypertriglycer-
idemia (age 51.4 6 3.1 years) and 75 normal subjects (age 52.2 6
1.7 years). We also studied platelet-dependent thrombin genera-
tion in patients with hypercholesterolemia before and after treat-
ment with pravastatin. Calcium chloride was added to 0.5 ml of
platelet-rich plasma (150 3 109/liter) to initiate coagulation. Ten
microliters of the sample was transferred into 90 ml of 3.8%
sodium citrate at 10-min intervals for 30 min. A chromogenic
substrate, S-2238, was added to each sample, and absorbance was
measured spectrophotometrically at a wavelength of 405 nm to
determine thrombin generation.
Results. Platelet-dependent thrombin generation was increased
in patients with hypercholesterolemia and patients with hypercho-
lesterolemia plus hypertriglyceridemia (p < 0.01) compared with
patients with hypertriglyceridemia and control subjects. Treat-
ment with pravastatin normalized thrombin generation.
Conclusions. Hypercholesterolemia, but not hypertriglyceride-
mia, was associated with increased platelet-dependent thrombin
generation. Pravastatin normalized the generation of thrombin.
(J Am Coll Cardiol 1997;30:91–6)
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Hyperlipidemia is a risk factor for atherosclerotic disease and
is often associated with myocardial infarction and cerebrovas-
cular disorders (1). The coagulation system has been proposed
as a possible mechanism of thrombogenesis and atherosclero-
sis in patients with hyperlipidemia. Some studies have demon-
strated increased coagulation activity and platelet function in
patients with hyperlipidemia (2–10), but others have produced
conflicting results (11–16). Thus, the roles of coagulation
factors and platelets in hyperlipidemia remain to be clarified.
Previous studies have measured coagulation activity and plate-
let function without examining their interactions. Aronson et
al. (17) have developed an experimental system for measuring
the platelet-dependent generation of thrombin to assess the
interaction between coagulation factors and platelets. In the
present study, we measure the platelet-dependent generation
of thrombin in patients with hypercholesterolemia to evaluate
the prothrombotic state in hyperlipidemic patients. We also
studied the effects of pravastatin, a lipid-lowering agent, on
thrombin generation to determine the relation between throm-
bin generation and hypercholesterolemia and to evaluate the
usefulness of the agent for resolving the prothrombotic state in
patients with hyperlipidemia.
Methods
Subjects. We studied 58 patients with hypercholesterol-
emia (total serum cholesterol level $220 mg/dl), 75 normal
subjects matched for age and gender (serum total cholesterol
level ,220 mg/dl, triglyceride level ,200 mg/dl), 37 patients
with hypertriglyceridemia (serum triglyceride level $200 mg/
dl) and 13 patients with both hypercholesterolemia and hyper-
triglyceridemia (Table 1). All subjects had normal thyroid,
hepatic and renal function, and none had underlying diseases,
such as ischemic heart disease, heart failure, inflammatory
disease, malignant tumors and diabetes mellitus. Subjects
received no medications known to affect platelet or coagula-
tion function or the metabolism of lipids in the 2 weeks before
blood collection. Pravastatin (15 mg/day) was administered to
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patients with hypercholesterolemia for at least 1 month, and
thrombin generation was compared before and after treat-
ment. Blood was collected from fasting subjects at 9 AM after
they had rested for at least 1 h. Smokers were requested to
abstain from smoking for at least 2 h before blood collection.
Informed consent was obtained from all subjects.
Measurement of thrombin generation. Thrombin genera-
tion was measured according to the method of Aronson et al.
(17), with slight modifications. Venous blood (3.8% sodium
citrate/blood 1:9) collected from patients and normal subjects
was centrifuged at 120g for 10 min at 22°C. Platelet-rich plasma
(PRP) was separated from the top two-thirds of the superna-
tant to avoid contamination by other cells, including mono-
cytes. The remaining blood was then centrifuged at 1,500g for
15 min to obtain platelet-poor plasma (PPP). The platelet
count in the PRP was determined with a Coulter counter
(S-Plas IV, Coulter Electronics), and the platelet concentra-
tion was adjusted to 150 3 109/liter with PPP after we
confirmed that the sample was not contaminated by other cells.
PRP aliquots (0.5 ml) were placed into round-bottomed
polypropylene tubes (12 3 75 mm), and 20 ml of 1 mol/liter
calcium chloride was added to initiate clotting; glass tubes were
not used because they would activate the intrinsic pathway of
coagulation cascade. Samples (10 ml) were added to the wells
of a microtiter plate containing 90 ml of 3.8% sodium citrate
at 10-min intervals for 30 min. Color was developed for
2 min by the addition of 50 ml of 0.5 mmol/liter S-2238
(H–D–Phe–Arg–NH–NO2–HCl, a thrombin-specific sub-
strate; Dai-ichi Kagaku Yakuhin, Tokyo, Japan) in 1 mol/
liter Tris (pH 8.1). The absorbance of the released color
product was measured spectrophotometrically at a wave-
length of 405 nm using a Vmax microtiter plate reader (Easy
Reader, EAR 340AT, SLT Lab Instruments GmbH, Vienna,
Austria). Measurements were obtained in triplicate at each
time point. The amount of thrombin generation was calcu-
lated from a standard curve.
Effect of pravastatin on thrombin generation in vitro. The
effect of pravastatin on thrombin generation was investigated
by measuring platelet-dependent thrombin generation after
incubating PRP obtained from normal subjects (n 5 4) with
pravastatin for 10 min. Pravastatin sodium (Sankyo Co., Ltd.,
Tokyo, Japan) was dissolved in physiologic saline and added
to PRP in concentrations of 10, 100 and 1,000 ng/ml (the
serum level of pravastatin in the clinical setting is ;20 to 50
ng/ml) (18). Physiologic saline was used as the control
vehicle.
Effects of pravastatin on platelet aggregability, prostaglan-
din production, phospholipids, lipoprotein(a) and platelet
activity in patients with hypercholesterolemia. We investi-
gated the effects of pravastatin in 15 patients with hypercho-
lesterolemia not accompanied by hypertriglyceridemia and in
13 age- and gender-matched normal subjects (Table 2). We
assessed the effects of pravastatin on subfractions of low and
high density lipoprotein cholesterol and investigated its effect
on platelet aggregability by measuring platelet aggregation in
response to 3 mg/ml of collagen (MC Medical Co., Ltd., Tokyo,
Japan), 1 mmol/liter of adenosine diphosphate (Sigma) and 1
mmol/liter of epinephrine (Dai-ichi Pharmaceuticals, Inc., To-
kyo, Japan), according to the method described by Born (19).
Prostaglandin production was assessed by measuring plasma
Abbreviations and Acronyms
beta-TG 5 beta-thromboglobulin
HDL 5 high density lipoprotein
HDL-2 5 high density lipoprotein, subfraction 2
LDL 5 low density lipoprotein
6-keto-PGF1alpha 5 6-keto-prostaglandin F1alpha
PF-4 5 platelet factor 4
PPP 5 platelet-poor plasma
PRP 5 platelet-rich plasma
t-PA–Ag 5 tissue-type plasminogen activator antigen
TX-B2 5 thromboxane B2

















Male/female 34/41 24/34 24/13 8/5
Age 52.2 6 1.7 56.5 6 1.5 59.5 6 1.7 51.4 6 3.1
T-Chol (mg/dl) 183.0 6 3.8 272.8 6 4.8* 219.1 6 4.1† 203.9 6 2.7 252.9 6 9.7*
TG (mg/dl) 105.2 6 5.9 162.9 6 14.2* 140.4 6 12.1 330.5 6 24.5* 340.3 6 25.7*
HDL-Chol (mg/dl) 58.6 6 2.8 54.2 6 2.0 54.6 6 1.7 46.7 6 2.2* 44.7 6 3.4
LDL-Chol (mg/dl) 115.3 6 4.9 189.3 6 5.1* 136.4 6 4.5† 108.6 6 6.9* 157.1 6 15.4*
TAT (ng/ml) 2.4 6 0.3 2.6 6 0.5 2.1 6 0.4 2.4 6 0.3 2.2 6 0.2
PIC (mg/ml) 0.9 6 0.1 0.8 6 0.1 0.9 6 0.1 0.9 6 0.1 1.1 6 0.2
t-PA–Ag (ng/ml) 3.1 6 0.8 3.2 6 0.9 2.9 6 0.7 3.1 6 0.8 3.4 6 0.8
*p , 0.01 versus normal group. †p , 0.01 versus before treatment. Data presented are mean value 6 SEM. HDL-Chol 5
high density lipoprotein cholesterol; Hyper-Chol 5 hypercholesterolemic; Hyper-TG 5 hypertriglyceridemic; LDL-Chol 5
low density lipoprotein cholesterol; PIC 5 plasmin-alpha2–plasmin complex; TAT 5 thrombin–antithrombin III complex;
T-Chol 5 total cholesterol; TG 5 triglycerides; t-PA–Ag 5 tissue-type plasminogen activator antigen.
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levels of thromboxane B2 (TX-B2) and 6-keto-prostaglandin
F1alpha (6-keto-PGF1alpha), according to the method described
by Powell (20). Platelet activity was determined by measuring
the serum levels of beta-thromboglobulin (beta-TG) and plate-
let factor 4 (PF-4), according to the method described by
Takahashi et al. (21).
Other markers of coagulation and fibrinolysis. Plasma
levels of thrombin–antithrombin III complex and plasmin-
alpha2–plasmin inhibitor complex were measured by enzyme
immunoassays using commercially available kits (Enzygnost-
TAT, Behringwerke AG, Marburg, Germany and PIC-test,
Teijin, Japan). The tissue-type plasminogen activator antigen
(t-PA–Ag) level was measured by a solid plasma enzyme
immunoassay using a commercially available kit (ELISA-tPA,
Technoclone, Austria). Measurements were obtained in hyper-
lipidemic patients and control subjects.
Statistical analysis. Results are shown as the mean
value 6 standard error (SEM). Data were analyzed by
repeated-measures analysis of variance for thrombin genera-
tion, and analysis of variance for other variables. When a
significant difference was observed, the Bonferroni/Dann
method was used for multiple comparisons. A p value ,0.01
was accepted as indicating statistical significance. Statistical
calculations were performed using StatView-J (version 4.02,
Abacus Concepts, Inc.).
Results
Platelet-dependent thrombin generation. Platelet-dependent
thrombin generation was significantly increased in patients
with hypercholesterolemia and those with hypercholesterol-
emia plus hypertriglyceridemia compared with thrombin gen-
eration in control subjects and patients with hypertriglyceride-
mia (p , 0.01) (Fig. 1). There was no significant difference in
platelet-dependent thrombin generation between patients with
hypercholesterolemia and those with hypercholesterolemia
plus hypertriglyceridemia, or between men and women (con-
trol group: 132 6 29 mIU/ml vs. 137 6 26 mIU/ml; patients
with hypercholesterolemia: 379 6 46 mIU/ml vs. 371 6
50 mIU/ml; patients with hypertriglyceridemia: 246 6 44
mIU/ml vs. 295 6 71 mIU/ml, respectively). Pravastatin re-
duced thrombin generation in patients with hypercholesterol-
emia to the control level (Fig. 2). Thrombin generation peaked at
the time of clot formation (568 6 20 mIU/ml) and remained high
thereafter. Clotting time after the addition of calcium chloride
was significantly shorter in patients before pravastatin adminis-
tration than in control subjects and patients after pravastatin
administration (control 67 6 4 min; pretreatment 37 6 4 min
[p , 0.01 vs. control and posttreatment groups]; posttreatment
59 6 5 min).
Effects of pravastatin on thrombin generation in vitro. Prav-
astatin had no effect on thrombin generation in vitro. Mean
thrombin level 30 min after addition of calcium chloride was 69 6 4
mIU/ml in control experiments, 86 6 15 mIU/ml in the
presence of 10 ng/ml of pravastatin, 67 6 16 mIU/ml in the
presence of 100 ng/ml of pravastatin and 63 6 10 mIU/ml in
the presence of 1,000 ng/ml of pravastatin. There were no
significant differences among groups, indicating that pravasta-
Figure 1. Platelet-dependent thrombin generation in patients with
hyperlipidemia. Platelet-dependent thrombin generation was in-
creased in patients with hypercholesterolemia (circles) and in those
with hypercholesterolemia plus hypertriglyceridemia (diamonds)
compared with that in patients with hypertriglyceridemia (trian-
gles) and control subjects (squares) *p , 0.01. Data shown are
mean value 6 SEM.
Table 2. Effect of Pravastatin on Platelet Aggregability,












Age 45.4 6 3.1 46.1 6 3.8
T-Chol (mg/dl) 192.4 6 5.7 250.0 6 6.8* 211.9 6 6.7†
TG (mg/dl) 138.9 6 7.1 152.6 6 6.3 148.3 6 6.8
HDL-Chol (mg/dl) 49.3 6 2.7 37.8 6 2.4* 43.8 6 3.4†
Subfraction 2 34 6 3 16 6 1* 19 6 2†
Subfraction 3 19 6 2 14 6 1 16 6 1
LDL-Chol (mg/dl) 113.8 6 6.5 170.6 6 11.7* 134.7 6 9.4†
Subfraction L 76 6 10 133 6 13* 90 6 12†
Subfraction S 32 6 6 38 6 12 39 6 8
Lipoprotein(a) (mg/dl) 16.1 6 4.7 16.6 6 4.6 16.6 6 5.0
Phospholipid (mg/dl) 195.4 6 3.5 277.5 6 6.0 248.0 6 10.1
Platelet aggregation
ADP (%) 77.8 6 5.3 66.0 6 7.8 86.4 6 3.8
Collagen (%) 85.6 6 4.5 78.7 6 8.8 93.5 6 2.6
Epinephrine (%) 75.0 6 7.0 77.5 6 5.9 72.7 6 8.7
Platelet activity
Beta-thrombo (ng/ml) 2.4 6 0.3 58.4 6 14.6 41.0 6 4.6
PF-4 (ng/ml) 0.9 6 0.1 19.3 6 7.7 9.4 6 1.8
TX-B2 (pg/ml) 3.1 6 0.8 12.6 6 1.5 15.6 6 4.3
6-keto-PGF1alpha (pg/ml) 3.1 6 0.8 8.1 6 2.6 10.6 6 1.1
*p , 0.01 versus normal subjects. †p , 0.01 versus pretreatment. Data
presented are mean value 6 SEM. ADP 5 adenosine diphosphate;
Beta-thrombo 5 beta-thromboglobulin; L 5 large; PF-4 5 platelet factor 4;
PGF1alpha 5 prostaglandin F1alpha; S 5 small; TX-B2 5 thromboxane B2; other
abbreviations as in Table 1.
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tin did not have direct effect on platelet-dependent thrombin
generation.
Effects of pravastatin on platelet aggregability, prostaglan-
din production and platelet activity in patients with hypercho-
lesterolemia. There was no significant difference in platelet
aggregability between pretreatment and posttreatment groups
(Table 2). There was no significant difference in platelet
activity assessed by measurement of plasma levels of beta-TG
and PF-4, or in prostaglandin production, assessed by mea-
surement of plasma levels of TX-B2 and 6-keto-PGF1alpha.
Effects of pravastatin on serum levels of low and high
density lipoprotein cholesterol subfractions, lipoprotein(a)
and phospholipids. The serum level of large, buoyant LDL
cholesterol was significantly decreased in patients with hyper-
cholesterolemia after treatment with pravastatin (p , 0.01).
The serum level of HDL, subfraction 2 (HDL-2) cholesterol
was significantly increased after treatment with pravastatin
(p , 0.01). There was no significant difference in serum levels
of lipoprotein(a) and phospholipids between pretreatment and
posttreatment groups (Table 2).
Other coagulation and fibrinolytic markers. There were no
significant differences in the plasma levels of thrombin–
antithrombin III complex, plasmin-alpha2–plasmin inhibitor com-
plex and t-PA–Ag among control subjects, patients with hyper-
cholesterolemia, patients with hypertriglyceridemia and patients
with hypercholesterolemia plus hypertriglyceridemia. There were
also no significant differences in these markers after treatment
with pravastatin in patients with hypercholesterolemia.
Discussion
Hyperlipidemia is a risk factor for ischemic heart disease,
suggesting that hypercoagulability may play a role in patients
with hyperlipidemia. However, previous studies (11–16,22–25)
using conventional methods of evaluating coagulation factors
and platelets, including measurement of coagulation markers
and platelet aggregability, have yielded conflicting results.
Thrombus formation results from the interaction between
platelets and various coagulation factors. Coagulation Factor
X is activated on platelet surfaces, and platelet factor 3
accelerates the conversion of prothrombin to thrombin (26,27).
Thrombin generated on activated platelets stimulates the
release of Factor Va from alpha-granules. Factor Va and
Factor Xa then convert prothrombin to thrombin, markedly
amplifying the coagulation cascade on the platelet membrane
(28). To investigate the interaction between coagulation fac-
tors and platelets, we used the method described by Aronson et
al. (17) to measure platelet-dependent thrombin generation in
patients with various types of hyperlipidemia.
Platelet-dependent thrombin generation in patients with
hyperlipidemia. In the present study, platelet-dependent
thrombin generation was increased in patients with hypercho-
lesterolemia and those with hypercholesterolemia plus hyper-
triglyceridemia. Thrombin generation was not increased in
patients with hypertriglyceridemia. Hypertriglyceridemia and
hypercholesterolemia did not have synergistic effects on
platelet-dependent thrombin generation. These results indi-
cate that hypercholesterolemia, but not hypertriglyceridemia,
was associated with increased thrombin generation in patients
with hyperlipidemia. No or little thrombin generation was
observed within 30 min in calcified PPP of control subjects and
patients with hypercholesterolemia (control subjects: 75 6 8
mIU/ml; patients 82 6 6 mIU/ml at 30 min after addition of
calcium chloride, n 5 12). These data are consistent with the
results of the previous study (17), confirming that platelets are
involved in thrombin generation in this system.
Effects of pravastatin on platelet-dependent thrombin gen-
eration. Pravastatin normalized platelet-dependent thrombin
generation in association with a reduction in the serum level of
cholesterol, confirming that hypercholesterolemia was associ-
ated with increased platelet-dependent thrombin generation.
Pravastatin did not affect the plasma levels of other lipopro-
teins, such as lipoprotein(a) and phospholipids, which is con-
sistent with the results of previous studies (29,30), and suggests
that lipoprotein(a) and phospholipids are not associated with
platelet-dependent thrombin generation.
Mechanisms of increased thrombin generation in patients
with hypercholesterolemia. Some studies have shown in-
creased platelet reactivity in patients with hypercholesterol-
emia (31–33), but others have shown conflicting results (8,34).
Previous studies (35,36) have shown that LDL cholesterol
increases platelet reactivity by stimulating phosphoinositide
turnover and increasing the cytosolic calcium concentration. In
the present study, we investigated the hypothesis that hyper-
cholesterolemia increased platelet reactivity. There were no
significant differences in platelet aggregability or plasma levels
of PF-4, beta-TG, TX-B2 and 6-keto-PGF1alpha, indexes of
platelet reactivity, between control subjects and patients with
hypercholesterolemia or before and after pravastatin treat-
ment in patients with hypercholesterolemia. However, we
could not conclude from these data that platelet aggregability
Figure 2. Platelet-dependent thrombin generation in patients with
hypercholesterolemia treated with pravastatin. Platelet-dependent
thrombin generation was higher in patients with pretreatment (circles)
than in control subjects (squares) *p , 0.01. Thrombin generation
tended to become closer to that in control subjects after treatment with
pravastatin (triangles). Data shown are mean value 6 SEM.
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or platelet activity was not increased in patients with hyper-
cholesterolemia for the following reasons: 1) the concentration
of the agonists used here was high enough to induce near-
maximal aggregation, and it was difficult to differentiate hyper-
aggregable platelets from normal ones; 2) variables such as
PF-4, beta-TG and TX-B2 could be increased easily by platelet
activation during blood collection, suggesting that these vari-
ables were unreliable as markers for platelet activity. Next, we
investigated another hypothesis that alterations in the subfrac-
tions of LDL cholesterol or HDL cholesterol might have
decreased thrombin generation. Previous studies have shown
that HDL-2 cholesterol decreased platelet aggregability (37)
and that small, dense LDL cholesterol increased an atheroge-
nicity (38). In the present study, the serum level of HDL-2
cholesterol was significantly increased in patients with hyper-
cholesterolemia after treatment with pravastatin. But this
change in HDL-2 cholesterol level was not reflected in platelet
aggregability because platelet aggregability was not changed
after treatment with pravastatin. Furthermore, there was no
significant difference in the serum level of small, dense LDL
cholesterol between pretreatment and posttreatment groups,
suggesting that small, dense LDL cholesterol was not respon-
sible for the change in thrombin generation. One proposed
mechanism is that alterations in the lipid–protein matrix and a
rearrangement of the lipid bilayer of platelets may stimulate
Factor Xa-induced conversion of prothrombin to thrombin in
patients with hypercholesterolemia (39). Further studies are
needed to investigate this possibility. Thus, we must assume
that the precise mechanisms of the increase in platelet-
dependent thrombin generation associated with hypercholes-
terolemia still remain unclear.
Study limitations. We used the method of Aronson et al.
(17) to assess hypercoagulability in patients with hypercholes-
terolemia. This method is based on the measurement of
thrombin generated by the addition of Ca21 ions to PRP. The
mechanism underlying increased platelet-dependent thrombin
generation in patients with hypercholesterolemia could not be
determined for the reasons described in the discussion section.
Also, whether a plasma factor is involved could not be deter-
mined because we did not conduct mixing experiments using a
mixture of control platelets plus patients’ plasma or a mixture
of patients’ platelets plus control plasma. Endothelial cells,
which modulate the prothrombotic state in vessels by produc-
ing various proteins, including thrombomodulin, plasminogen
activator inhibitor-1 and tissue-type plasminogen activator are
not present in this system, and thus, we did not examine the
interaction between endothelial cells and platelets. Other
important factors, such as shear stress and whole-blood fluid-
ity, were also not considered. Further studies are needed to
evaluate these factors.
Conclusions. Platelet-dependent thrombin generation
was increased in patients with hypercholesterolemia, indi-
cating that hypercholesterolemia is associated with hyper-
coagulability through the interaction between platelets and
coagulation factors. Increased thrombin generation in pa-
tients with hypercholesterolemia was normalized by treat-
ment with pravastatin, suggesting that pravastatin may be
useful for the prevention of thrombotic complications in
hypercholesterolemic patients.
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